Lancet HIV

Article	Citations
Tackling cancer risk in adolescents and young adults with HIV	197
Invest in HIV now to reap future rewards	174
Inherited fear: 40 years of HIV/AIDS in the UK	154
The time to end the war on drugs is long overdue	131
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	125
A new initiative to track HIV resource allocation	125
Highlights of HIV Drug Therapy 2022	123
Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study	119
Treating HIV-associated tuberculosis in children without compromise	118
Optimising HIV spending in eastern Europe and central Asia	114
Reflections on a decade of The Lancet HIV	106
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	106
A career dedicated to public service	91
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother–infant pairs (MTN-043): a phase 3B, open-label, randomised trial	87
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-labe	86
PEPFAR reauthorisation hangs in the balance	84
Planning for PrEP: are national surveillance data sufficient?	80
UNAIDS strategy aligns HIV priorities with development goals	78
Empowering women: addressing HIV vertical transmission in the Philippines	76
Dolutegravir for children with HIV-associated tuberculosis	75
Gone but not forgotten	75
Zvandiri—when medicines alone are not enough	63
How much could long-acting PrEP cost in South Africa?	61
AIDS activism from the beginning	59
Combination HIV prevention reduces orphanhood in Uganda	57

HIV and mental health services for female sex workers	55
Transitioning youth living with HIV to adult HIV care	55
The Australian AIDS crisis through the eyes of volunteers	54
HIV-related CNS infections: translating DREAMM into reality	53
Risk estimation in HIV reveals our usual blind spots	51
Steps toward quick and equitable roll-out of lenacapavir	48
Controversial chronicler of LGBTQ rights	47
Interpreting unit costs of PrEP services by effective use	47
The Háttér Society: supporting LGBTQ people in Hungary	44
UK HIV transmission drops in the wake of COVID-19	42
Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012–19): a longitudinal cohort study	41
All the viral loads we cannot see	41
Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial	41
Ageing with HIV: is the virus or the treatment guilty?	40
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a pha	40
Evidence supports use of on-demand PrEP for HIV prevention	40
Community mobilisation to achieve HIV testing and care goals	40
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study	40
Low-cost urine tenofovir assay to triage dolutegravir resistance testing	39
PrEParing for choice in a new era of HIV prevention	39
Lenacapavir plus two bNAbs: feasible, with some caveats	38
Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, op	38
Antiretrovirals and obesity	37
Multilevel interventions for young people with HIV	36
Anything but pro-life	36
Emergent HIV drug resistance in non-inferiority trials	35
Marking 40 years of the HIV/AIDS response	34
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analy	34
Prophylactic HIV-1 vaccine trials: past, present, and future	32
Argentina updates HIV laws	32
How do we prevent anal cancer in people living with HIV?	32
Supporting Poland's LGBT+ community through thick and thin	31
Effects of long-term antiretroviral therapy in reproductive-age women in sub-Saharan Africa (the PEPFAR PROMOTE study): a multi-country observational cohort study	30
Insights on COVID-19 mortality and HIV from South Africa	30
Successes and challenges in Thailand's HIV response	29
Expanding options of child-friendly, single-tablet regimens for young children with HIV	29
Highlights from CROI 2024	29
Enhancing HIV care with incentives: one size does not fit all	29
Lung cancer in people living with HIV	28
Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19	28
Navigating the AIDS crisis with open hearts	28
A pioneer for sexuality, race, and identity	28
HIV PrEP and viral hepatitis: a unique opportunity for integration	28
HIV viral suppression is key to healthy longevity	28
Highlights of the 19th European AIDS Conference	27
Lenacapavir: an attractive option, but proceed with caution	27
LVCT Health: implementing PrEP in Kenya	26
Are we ready for long-acting HIV treatment for adolescents?	26
Tajikistan faces a crucial moment in HIV/AIDS response	26
Thailand's commitment to support community-led HIV services	25

Transplant donation without discrimination	24
Towards no missed opportunities: the experience of 56 Dean Street	24
Gender-affirming HIV care as a tool to end the HIV epidemic	23
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	23
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use	23
ART and cardiovascular-disease risk in people with HIV	23
Ending HIV in Chicago by 2030	23
The power of peers at prison exit	22
Improving outcomes for children in families with HIV	22
Optimising anal cancer screening through risk stratification	21
Improving quality of interpersonal care in HIV programmes	21
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1	21
Lymphomas included in the AIDS case definition: an update 30 years later	21
Experiences of HIV among global Indigenous populations through the lens of the UN Declaration on the Rights of Indigenous Peoples	21
Helping hospitals heal people with HIV and tuberculosis	21
Prioritise people with HIV for COVID-19 vaccination	21
Implied consent for HIV testing in the UK: time for a new approach?	21
Forgiveness of an intermittent HIV treatment strategy	20
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gon	20
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	20
Intertwined epidemics: progress, gaps, and opportunities to address intimate partner violence and HIV among key populations of women	20
The effects of cash transfer programmes on HIV/AIDS prevention and care outcomes: a systematic review and meta-analysis of intervention studies	20
Effect of climate change on the HIV response	20
Dolutegravir once daily with rifampicin for HIV and tuberculosis	20
Correction to Lancet HIV 2023; 10: e424–26	19
Interventions to ensure access to and continuity of HIV care for international migrants: an evidence synthesis	19
Correction to Lancet HIV 2022; 9: e791–800	19
Correction to Lancet HIV 2024; 11: e86–95	18
Correction to Lancet HIV 2023; 10: e713–22	18
Correction to Lancet HIV 2022; 9: e79–90	18
Increased risk of mental illness in people with HIV	17
Correction to Lancet HIV 2024; 11: e233–44	17
Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study	17
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial	17
HIV and COVID-19: juxtaposition of two pandemics	17
Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis	17
Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95-95-95 targets in Malawi among individuals aged 15–64 years: population-based HIV impact assessments, 2015−16 and 2020−21	16
Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study	16
Drug-level feedback counselling: modest support to PrEP adherence	16
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	16
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	14
Voucher incentives to improve viral suppression among HIV-positive people who inject drugs and men who have sex with men in India: a cluster randomised trial	14
Tailoring care for frail and lonely older people with HIV in Canada: a cross-sectional study	14
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study	14
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	14
Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study	14
The long wait for long-acting HIV prevention and treatment formulations	14
Call for justice-informed HIV cure trials with ATIs	14
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration	13
HIV seropositivity and viral non-suppression in transgender, non-binary, and gender-diverse people in primary care receiving gender-affirming hormone therapy in the USA between 2013 and 2019 (LEGACY):	13
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	13
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	13
Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial	13
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind,	13
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19	13
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a dou	13
International Women's Day—how can I help?	12
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial	12
Where does doravirine fit in current antiretroviral therapy?	12
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	11
A public health approach to drug use crucial to ending AIDS	11
Game-changing study of second-line HIV treatment	11
Improving outcomes after hospitalisation in people with HIV	11
Real-world safety of pre-exposure prophylaxis for HIV	11
Ending HIV in the UK	11
HIV/AIDS cast a dark shadow on 1980s London gay culture	11
Africa and AIDS: still much work to be done	11
Moving forward with dolutegravir in children weighing less than 20 kg	11
AIDS activism through art	10
COVID-19 antivirals must not affect HIV drug supply	10
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	10
UK and US militaries update HIV policies	10
Innovation is important, but so is access	10
PrEP for men who have sex with men in Africa	10
Outdated attitudes to HIV must change	10
Home delivery of ART: could this be a reality in South Africa?	10
Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional ana	10
Equitable access to PrEP is essential to reap its benefits	10
Unheard testimony	10
Bridging accessibility gaps in HIV prevention	9

Gradual improvements in HIV outcomes for African GBMSM	9
All roads lead to Westminster: the infected blood scandal	9
PrEP empowering female sex workers in Kenya	9
Implementation of HIV prevention strategies globally	9
Trump executive orders cast doubt on PEPFAR's future	9
Reassessing oral lead-in for injectable long-acting HIV therapy	9
Using life course events to target HIV services	9
Putting people first in communication about HIV	8
Lessons from the HPTN 071 (PopART) trial	8
Social determinants of transgender women's health	8
Highlights of IAS 2023	8
A second decade of PrEP	8
To give or not to give: what is the evidence?	8
Integration of sexual health and HIV services	8
Ethical trial design for the future	8
Gains and gaps: addressing HIV in diverse sex worker groups	8
Equitable access to long-acting PrEP on the way?	8
Highlights of virtual CROI 2022	8
Defining principles for a choice-based approach to HIV prevention	8
SARS-CoV-2 immunity and HIV infection: total recall?	8
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	8
Stigma reduction is key to improving the HIV care continuum	7
Tangerine Clinic: championing transgender health care	7
Reaching the third 95 using community ART delivery models	7
Fate of people with HIV in jeopardy in Ukraine	7
What future for HIV vaccines?	7
Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial	7
Reducing HIV transmission in British Columbia, Canada	7
Compelling evidence for unconditional shift to dolutegravir	7
Response to Thailand's commitment to support community-led HIV services	7
Time to tackle late diagnosis	7
More evidence for worse COVID-19 outcomes in people with HIV	7
Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa	7
Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019	7
Disparities in approaches to ART access in Europe	7
Living authentically despite prejudice and marginalisation	7
Refugees from Ukraine: children and adolescents with HIV in Germany	7
Menopausal hormone therapy for women living with HIV	6
UK emergency department testing for HIV expanded	6
Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study	6
Monkeypox vaccination—an opportunity for HIV prevention	6
Optimising oral PrEP while awaiting long-acting cabotegravir	6
Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study	6
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-	6
Life-expectancy with HIV in Latin America and the Caribbean	6
Need for transgender-specific data from Asia	6
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk	6
Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians	6
HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study	6
Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled t	6
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	6
Expansion of PrEP and PEP services in China	5
Antiretroviral efficacy versus neurotoxicity	5
Long-acting PrEP: new opportunities with some drawbacks	5
Correction to Lancet HIV 2023; 10: e375–84	5
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	5
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	5
Brain not exempt from social determinants of health	5
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	5
Anti-LGBT laws continue to hinder the HIV response	5
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial	5
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	5
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	5
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	5
Redefining care: injectable HIV treatment for adolescents	5
HIV self-testing, PrEP, and drug resistance: some insights	5
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study	5
Extreme weather events and disruptions to HIV services: a systematic review	5
Correction to Lancet HIV 2018; 5: e488–97	5
Sex as a biological variable in HIV-1 and schistosome co-infection	5
Screening for chlamydia and incidence of symptomatic infections	5
Artificial intelligence powers HIV testing services in Kenya	5
Ensuring the right to health for migrants and refugees	5
Suicide prevention research is crucial to achieving health equity for people with HIV	4
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study	4
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study	4
Causes of hospitalisation among people living with HIV worldwide, 2014–23: a systematic review and meta-analysis	4
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study	4
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis	4
Highlights from the 11th IAS Conference on Science	4
Tuberculosis disease among people with HIV: therapeutic advances	4
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	4
Recent gay Black history in the UK	4
The effect of providing women sustained access to HIV self-tests on male partner testing, couples testing, and HIV incidence in Kenya: a cluster-randomised trial	4
Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study	4
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial	4
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis	4
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	4
Modelling study shows staggering impact of HIV funding cuts	4
The best place for doravirine	4
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	4
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium	4
Mexican perspective on the Mosaico HIV vaccine trial	4
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	4
Person-centred care for older adults living with HIV in sub-Saharan Africa	4